Starting a career in hedge funds demands a combination of education, experience, and knowledge prerequisites. With it, a bit of luck is always appreciated. A hedge … ...

In his weekly commentary released Monday, Wharton Professor Siegel warned that Democrats have "thrown a monkey wrench" into budget negotiations, threatening a new government shutdown. While markets ...

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or ...

Laura Mendoza, a legal representative for the Iowa Migrant Movement for Justice, speaks against a bill Wednesday at the Iowa Capitol in Des Moines. The bill would require the Iowa Department of ...

Multiple current and former Target employees have reached out to BleepingComputer to confirm that the source code and documentation shared by a threat actor online match real internal systems. A ...

OpenAI continues its push into healthcare with the launch of ChatGPT Health, a new feature that connects its artificial intelligence chatbot with users' medical records and wellness apps for more ...

What if you could break free from subscription fees, vendor lock-in, and row limits while still managing your data with the ease of a spreadsheet? Better Stack walks through how an open source ...

A monthly overview of things you need to know as an architect or aspiring architect. Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with ...

Guess what! Inflation, growth, jobs: Conventional wisdom from America’s economic punditry was across-the-board wrong. Again. At the year’s start the punditry predicted that Trump’s tariffs would cause ...

Security expert Troy Hunt just added a huge new dataset to the Have I Been Pwned database containing 183 million new email accounts with leaked login details. It was collected with the help of ...

Deucravacitinib was associated with improvements in clinical responses and patient reported outcomes, as well as inhibition of radiographic progression, when compared with placebo. Deucravacitinib was ...